| Literature DB >> 27373157 |
Nadine S Jahchan1, Jing Shan Lim1, Becky Bola2, Karen Morris2, Garrett Seitz1, Kim Q Tran1, Lei Xu1, Francesca Trapani2, Christopher J Morrow2, Sandra Cristea1, Garry L Coles1, Dian Yang1, Dedeepya Vaka1, Michael S Kareta1, Julie George3, Pawel K Mazur1, Thuyen Nguyen1, Wade C Anderson4, Scott J Dylla4, Fiona Blackhall5, Martin Peifer3, Caroline Dive2, Julien Sage6.
Abstract
Small cell lung cancer (SCLC) is a neuroendocrine lung cancer characterized by fast growth, early dissemination, and rapid resistance to chemotherapy. We identified a population of long-term tumor-propagating cells (TPCs) in a mouse model of SCLC. This population, marked by high levels of EpCAM and CD24, is also prevalent in human primary SCLC tumors. Murine SCLC TPCs are numerous and highly proliferative but not intrinsically chemoresistant, indicating that not all clinical features of SCLC are linked to TPCs. SCLC TPCs possess a distinct transcriptional profile compared to non-TPCs, including elevated MYC activity. Genetic and pharmacological inhibition of MYC in SCLC cells to non-TPC levels inhibits long-term propagation but not short-term growth. These studies identify a highly tumorigenic population of SCLC cells in mouse models, cell lines, and patient tumors and a means to target them in this most fatal form of lung cancer.Entities:
Mesh:
Year: 2016 PMID: 27373157 PMCID: PMC4956576 DOI: 10.1016/j.celrep.2016.06.021
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423